Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley H D, Graham J E
Division of Gynecologic Oncology, University of Southern California Medical School, Los Angeles.
Gynecol Oncol. 1991 Jan;40(1):55-65. doi: 10.1016/0090-8258(91)90086-k.
Between June 20, 1977 and February 5, 1983, the Gynecologic Oncology Group entered 1180 women with clinical stage I or II (occult) endometrial carcinoma into a surgical-pathological staging study. Eight hundred ninety-five patients with endometrioid or adenosquamous carcinoma were evaluable for this study which relates surgical-pathological parameters and postoperative treatment to recurrence-free interval and recurrence site. Proportional hazards modeling of time to recurrence was performed. For patients without metastasis determined by surgical-pathological staging the greatest determinant of recurrence was grade 3 histology adenocarcinoma grade 3, relative risk (RR) = 15; adenosquamous carcinoma grade 3, RR = 8.1; all adenocanthomas, RR = 1.0). Of 48 patients with histologically documented aortic node metastases, 47 had one or more of the following features: (1) grossly positive pelvic nodes, (2) grossly positive adnexal metastasis, or (3) outer one-third myometrial invasion. Pelvic radiation was administered to 48.0% and vaginal brachytherapy alone to 10.2% of patients postoperatively; 41.8% received no adjuvant radiation therapy. None of three recurrences in the vaginal implant group were vaginal or pelvic; 7.4% (7 of 95) of recurrences in the pelvic radiation therapy (RT) group were vaginal and 16.8% were pelvic; 18.2% (8 of 44) of recurrences in the no adjuvant radiation group were vaginal and 31.8% pelvic. Because of the high degree of selection bias no valid comparisons can be made of recurrence-free interval in these groups. The 5-year recurrence-free interval for patients with negative surgical-pathological risk factors (other than grade and myoinvasion) was 92.7%; involvement of the isthmus/cervix 69.8%; positive pelvic cytology 56.0%; vascular space invasion 55.0%; pelvic node or adnexal metastases 57.8%; and aortic node metastases or gross laparotomy findings 41.2%. It is not clear that cervix invasion per se diminishes survival, because it is more often associated with poor tumor differentiation (34.7% versus 24.0%, grade 3) and deep myoinvasion (47.0 vs 18.6%) than cases without cervix invasion. The relapse rate among cervix-positive and -negative cases with grade 3 lesions and deep myoinvasion is not dramatically different (48.8% vs 39.8%). The proportion of failures which were vaginal/pelvic (34.6% for the surgery only group compared to 12.5% of the RT group) appears to favor the use of adjuvant radiation for patients with more than one-third myoinvasion and grade 2 or 3 tumor. There were 97 patients in the study group with malignant cytology of which 29.1% had regional/distant failure, which compares to 10.5% of the cytology-negative patients.(ABSTRACT TRUNCATED AT 400 WORDS)
1977年6月20日至1983年2月5日期间,妇科肿瘤研究组将1180例临床I期或II期(隐匿性)子宫内膜癌患者纳入一项手术病理分期研究。895例子宫内膜样癌或腺鳞癌患者可用于本研究,该研究将手术病理参数和术后治疗与无复发生存期及复发部位相关联。对复发时间进行了比例风险建模。对于经手术病理分期确定无转移的患者,复发的最大决定因素是3级组织学腺癌(3级,相对风险[RR]=15);腺鳞癌3级,RR=8.1;所有腺棘皮瘤,RR=1.0)。在48例有组织学记录的主动脉旁淋巴结转移患者中,47例具有以下一项或多项特征:(1)盆腔淋巴结大体阳性,(2)附件大体转移阳性,或(3)肌层外三分之一浸润。术后48.0%的患者接受盆腔放疗,10.2%的患者仅接受阴道近距离放疗;41.8%的患者未接受辅助放疗。阴道植入组的3例复发均不在阴道或盆腔;盆腔放疗(RT)组7.4%(95例中的7例)的复发在阴道,16.8%在盆腔;未接受辅助放疗组18.2%(44例中的8例)的复发在阴道,31.8%在盆腔。由于高度的选择偏倚,无法对这些组的无复发生存期进行有效比较。手术病理危险因素(除分级和肌层浸润外)为阴性的患者5年无复发生存率为92.7%;峡部/宫颈受累为69.8%;盆腔细胞学阳性为56.0%;血管间隙浸润为55.0%;盆腔淋巴结或附件转移为57.8%;主动脉旁淋巴结转移或大体剖腹探查结果为41.2%。宫颈浸润本身是否会降低生存率尚不清楚,因为与无宫颈浸润的病例相比,它更常与肿瘤分化差(34.7%对24.0%,3级)和深部肌层浸润(47.0对18.6%)相关。3级病变和深部肌层浸润的宫颈阳性和阴性病例的复发率没有显著差异(48.8%对39.8%)。阴道/盆腔失败的比例(仅手术组为34.6%,而RT组为12.5%)似乎支持对肌层浸润超过三分之一且肿瘤为2级或3级的患者使用辅助放疗。研究组中有97例患者细胞学为恶性,其中29.1%有区域/远处失败,而细胞学阴性患者为10.5%。(摘要截取自400字)